RenovoRx Business Summary

RenovoRx, Inc. (RNXT) is a clinical-stage biopharmaceutical company that has recently transitioned into a commercial-stage entity, generating revenue primarily through the direct sale of its FDA-cleared RenovoCath drug-delivery device to leading cancer centers. The company’s business model is centered on its proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which facilitates the localized delivery of chemotherapy to solid tumors. Its primary business segments include commercial medical device sales and the development of its lead Phase III product candidate, RenovoGem, a drug-device combination targeting locally advanced pancreatic cancer. RenovoRx competes directly with interventional oncology and biotech firms such as TriSalus Life Sciences, Tenaya Therapeutics, Corbus Pharmaceuticals, and Vor Biopharma. Within this landscape, RenovoRx distinguishes itself by focusing on pressure-mediated delivery systems designed to bypass systemic toxicities, positioning it as a niche leader in targeted interventional oncology for high unmet medical needs. The company was co-founded in 2009 by interventional cardiologist Ramtin Agah, M.D., who serves as Chief Medical Officer and Chairman, and Kamran Najmabadi. The leadership team is spearheaded by CEO Shaun R. Bagai, who brought extensive market development experience from HeartFlow and Medtronic (via Ardian) upon joining in 2014. In February 2026, the executive suite was further strengthened by the appointment of Mark Voll as Chief Financial Officer, a seasoned public company executive with a track record of leading IPOs and exits for firms like Aquantia and Montage Technology. RenovoRx is supported by a robust board of directors, including notable members such as serial biotech CEO Una S. Ryan, O.B.E., and former Schering-Plough CMO Robert J. Spiegel, M.D. Major institutional investors include AWM Investment Company, AIGH Capital Management, and Vanguard Group, reflecting significant institutional interest in the company’s TAMP platform.